Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O1GS
|
|||
| Former ID |
DNCL001582
|
|||
| Drug Name |
Fulranumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Arthralgia [ICD-11: ME82; ICD-10: M25.5] | Phase 3 | [1] | |
| Back pain [ICD-11: ME84.Z] | Phase 3 | [1] | ||
| Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Phase 3 | [1] | ||
| Company |
Johnson & Johnson Pharmaceutical Research & Development
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Low-affinity nerve growth factor receptor (NGFR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| NRAGE signals death through JNK | ||||
| p75NTR negatively regulates cell cycle via SC1 | ||||
| Regulated proteolysis of p75NTR | ||||
| NADE modulates death signalling | ||||
| NRIF signals cell death from the nucleus | ||||
| p75NTR recruits signalling complexes | ||||
| NF-kB is activated and signals survival | ||||
| Axonal growth stimulation | ||||
| WikiPathways | Spinal Cord Injury | |||
| BDNF signaling pathway | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02336685) Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.